Medicortex was granted a European patent for detection of biomarker indicative to brain injury

Medicortex’s TBI diagnostics patent “A Method for Determining a Lectin-binding Glycan Indicative to Traumatic Brain Injury” was granted by the European Patent Office (EP patent No. 4133279). The patent protects a technique for detecting certain carbohydrates in a sample, allowing for non-invasive analysis of a bodily fluid, such as urine or saliva, for the presence and the level of biomarkers that are indicative of TBI.

Once again, Medicortex has received confirmation of its strength in patent protecting the innovations and new technologies it has developed in-house by its experienced research team.

Dr. Harel, CEO of Medicortex: “This is a great achievement - we are very pleased with the increase of our patent portfolio, the intellectual property covering methods of using certain biomarkers for detection of concussion and TBI. Issuance of this patent is another important step in the development of a new strategy to help identify and treat TBI.”

Medicortex’s patent portfolio encompasses biomarkers and methods of TBI detection as well as drug candidates developed by the company for halting the progression of TBI. The comprehensive patent coverage secures exclusivity to develop the products, and the company’s strategy is to actively seek new patentable innovations from its biomarker and drug development programs.